AUA 2020: Benchmarking Current Nephrectomy Practice in Malignant Disease in England: An Analysis of the BAUS Complex Operation Registry

(UroToday.com) Public reporting of surgical outcomes is controversial in North America but widely mandated in England as the basis of the ‘Consultant Outcomes Publication’. In this publication, urologists in England performing nephrectomy for cancer are mandated in providing public-facing outcome data. The BAUS complex operations registry is a nationally held repository, providing contemporary benchmarking data to […]

AUA 2020: Expanding Kidney-Sparing Options for Patients with Low-Grade Upper Tract Urothelial Cancer

(UroToday.com) In a sponsored educational session at the American Urologic Association Virtual Annual Meeting, Karim Chamie, MD, presented on the recently expanded kidney-sparing options for patients with low-grade upper tract urothelial cancer. To begin, Dr. Chamie highlighted the evolution in thinking regarding kidney sparing treatment for patients with upper tract urothelial cancer (UTUC). While kidney-sparing […]

Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy for Prostate Cancer: Current Status and Perspectives.

Prostate cancer is the most common cancer to affect men in the United States and the second most common cancer in men worldwide. Prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging is gradually recognized as a novel technique that can improve treatment decisions and affect clinical care of prostate cancer patients as the PSMA […]

Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials.

To assess reasons patients do not consent to patient-report outcome (PRO) and electronic PRO data capture components of clinical trials and potential selection bias by having a separate consent. Selected XXXX trials were included based on disease site and inclusion of PROs and electronic PRO data capture via VisionTree Optimal Care (VTOC; VisionTree Software, Inc, […]

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.

With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib-ICI combinations.

X